Skip to main content

Advertisement

SpringerLink
Log in

Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background In the case of psoriatic patients, only a limited number of studies have related serum biological therapies and antidrug antibodies levels to clinical response. With respect to etanercept, the available evidence has not shown any relationship yet. Objective The aim of this study was to determine if there is any correlation among etanercept serum levels, the presence of anti-etanercept antibodies and clinical response to this treatment in psoriatic patients. Setting A 1500-bed hospital (A Coruña University Hospital Complex). Method A retrospective observational study in psoriatic patients treated with etanercept (50 mg once weekly) was carried out. Psoriasis Area and Severity Index scale and adverse reactions were recorded at the time of the extraction sample. The pharmacokinetic monitoring was evaluated at the previous time points by extracting peripheral blood samples before the dose administration. Etanercept and anti-etanercept antibodies concentrations were quantified by two sandwich-type ELISA immunoassays. The patients were classified into three groups (good, partial and nonresponders) in accordance with the treatment efficacy at the blood assessment moments. The Kruskall-Wallis test and Spearman correlation assay were used to assess the efficacy and incidence of adverse effects according to the etanercept concentration and anti-etanercept antibodies, considering p values of <0.05 as statistically significant. This statistical analysis was conducted using SPSS software (version19.0). Main outcome measures Etanercept and anti-etanercept antibodies trough serum levels and clinical response. Results 38 patients were included. 26 patients (68.4 %) were good, 5 (13.2 %) were partial and 7 (18.4 %) were non-responders. There was no significant difference with respect to etanercept levels: 2.7 μg/mL (range 0.7–5.6) versus 2.2 μg/mL (range 1.0–3.5) versus 1.73 μg/mL (range 0.1–2.3), respectively (p = 0.085). Nevertheless, a positive correlation between percentage decrease in the Psoriasis Area and Severity Index scale value with respect to the baseline value and etanercept concentration was found (p = 0.011). No anti-etanercept antibodies were detected; nor was there a significant difference in the incidence of adverse effects (p = 0.8523). Conclusions Our results showed a positive correlated between etanercept concentration and the percentage decrease in the Psoriasis Area and Severity Index scale value. The incidence of anti-etanercept antibodies in psoriatic patients was low.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aikawa NE, de Carvalho JF, Almeida Silva CA, Bonfá E. Immunogenicity of anti-TNF-α agents in autoinmune diseases. Clin Rev Allergy Immunol. 2010;38:82–9.

    Article  Google Scholar 

  2. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept, a single centre, cohort study. Br J Dermatol. 2013;169:306–13.

    Article  CAS  PubMed  Google Scholar 

  3. Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients a preliminary study. G Ital Dermatol Venereol. 2013;148:171–4.

    CAS  PubMed  Google Scholar 

  4. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of antiTNF therapy in immune-mediated inflammatory diseases a systematic review of the literature with a metaanalysis. Ann Rheum Dis. 2013;72:1947–55.

    Article  PubMed  Google Scholar 

  5. Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164–72.

    Article  PubMed  Google Scholar 

  6. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–35.

    Article  CAS  PubMed  Google Scholar 

  7. Haraoui B, Cameron L, Ouellet M, White B. Antiinfliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31–6.

    CAS  PubMed  Google Scholar 

  8. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74:e16.

    Article  PubMed  Google Scholar 

  9. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–21.

    Article  CAS  PubMed  Google Scholar 

  10. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.

    Article  PubMed  Google Scholar 

  11. Van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021–8.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284–8.

    Article  CAS  PubMed  Google Scholar 

  13. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445–52.

    Article  CAS  PubMed  Google Scholar 

  14. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in crohn’s disease. Gastroenterology. 2009;137:1628–40.

    Article  CAS  PubMed  Google Scholar 

  15. Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(80–4):e2.

    PubMed  Google Scholar 

  16. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–53.

    Article  CAS  PubMed  Google Scholar 

  17. Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–8.

    Article  CAS  PubMed  Google Scholar 

  18. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–6.

    Article  CAS  PubMed  Google Scholar 

  19. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–9.

    Article  CAS  PubMed  Google Scholar 

  20. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.

    Article  CAS  PubMed  Google Scholar 

  21. Menting SP, van Lümig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis: one-year follow up. JAMA Dermatol. 2014;150:130–6.

    Article  CAS  PubMed  Google Scholar 

  22. Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol. 2013;40:389–92.

    Article  PubMed  Google Scholar 

  23. Elberdín L, Outeda M, Salvador P, Paradela S, Fernández-Torres RM, Iglesias R, et al. Infliximab drug and antibody levels in patients with dermatological conditions. Int J Clin Pharm. 2015;37:320–6.

    Article  PubMed  Google Scholar 

  24. Adisen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients. pilot study. J Dermatol. 2010;37:708–13.

    Article  CAS  PubMed  Google Scholar 

  25. Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92:362–4.

    Article  CAS  PubMed  Google Scholar 

  26. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39–42.

    Article  CAS  PubMed  Google Scholar 

  27. Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9:949–58.

    Article  CAS  PubMed  Google Scholar 

  28. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis a systematic review. Br J Dermatol. 2014;170:261–73.

    Article  CAS  PubMed  Google Scholar 

  29. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48:1267–81.

    Article  CAS  PubMed  Google Scholar 

  30. Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramírez CS, Heredia ES, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med. 2012;50:1845–7.

    Article  CAS  PubMed  Google Scholar 

  31. Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009;100:386–413.

    Article  CAS  PubMed  Google Scholar 

  32. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71:88–91.

    Article  CAS  PubMed  Google Scholar 

  33. Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, Morel J. Etanercept concentration in patients with AR and its potencial influence on treatment decisions: a pilot study. J Rheumatol. 2012;39:1533–8.

    Article  PubMed  Google Scholar 

  34. Detrez I, Brouwers E, Peeters M, Geukens N, de Vlam K, Gils A. Characterization and application of a unique panel of monoclonal antibodies generated against etanercept. J Immunol. 2016;196:2879–84.

    Article  CAS  PubMed  Google Scholar 

  35. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:531–5.

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Pharmacy Department, A Coruña University Hospital Complex, Integrated Administration Management, As Xubias, 86, 15006, A Coruña, Spain

    Laida Elberdín, Maria Outeda, Pilar Salvador & Isabel Martín

  2. Dermatology Department, A Coruña University Hospital Complex, Integrated Administration Management, As Xubias, 86, 15006, A Coruña, Spain

    Sabela Paradela, Rosa María Fernández-Torres, Raquel Iglesias & Eduardo Fonseca

Authors
  1. Laida Elberdín
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Outeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pilar Salvador
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabela Paradela
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosa María Fernández-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raquel Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eduardo Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Isabel Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laida Elberdín.

Ethics declarations

Conflicts of interest

Sabela Paradela, Rosa M. Fernandez-Torres and Eduardo Fonseca have participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis and in continuing medical education events supported by unrestricted educational grants from Abbvie, Celgene, Janssen-Cilag, Leo, MSD and Pfizer. The other authors have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elberdín, L., Outeda, M., Salvador, P. et al. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value. Int J Clin Pharm 38, 1142–1148 (2016). https://doi.org/10.1007/s11096-016-0343-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-016-0343-0

Keywords

Search

Navigation